达格列净对2型糖尿病合并急性冠脉综合征患者PCI后急性肾损伤及预后的影响 点击下载
| 论文标题： | 达格列净对2型糖尿病合并急性冠脉综合征患者PCI后急性肾损伤及预后的影响 |
| 英文标题： | |
| 中文摘要： | 目的 探讨达格列净对2型糖尿病（T2DM）合并急性冠脉综合征（ACS）患者行经皮冠状动脉介入治疗（PCI）后造影剂诱导的急性肾损伤（CIAKI）以及预后的影响。方法回顾性收集2021年1月1日至2022年12月31日于天津市胸科医院心内科行PCI治疗的T2DM合并ACS患者资料，根据患者有无应用达格列净，分为达格列净组（96例）和对照组（148例）。记录所有患者PCI前及PCI后48h、1周的肾功能指标，包括血尿素氮（BUN）、血肌酐（Scr）、估算的肾小球滤过率（eGFR）、胱抑素C（Cys-C）、肾损伤分子1（KIM-1）、β2微球蛋白（β2-MG）。所有患者至少随访1年。记录2组患者CIAKI及随访期间主要心血管不良事件（MACE）的发生情况。应用Logistic回归分析使用达格列净对CIAKI发生情况的影响，应用Log-rank检验比较2组之间MACE发生情况的差异，应用Cox回归分析使用达格列净对患者预后的影响。结果PCI后48h及1周，达格列净组患者血Cys-C、KIM-1、β2-MG水平均显著低于对照组（P＜0.05）。达格列净组患者CIAKI的发生率显著低于对照组（6.25%vs.14.86%，P＝0.042）；Logis‐tic回归分析结果显示，使用达格列净是CIAKI的独立保护因素（OR＝0.280，95%CI为0.101～0.780，P＝0.015）。随访期间达格列净组患者MACE的发生率显著低于对照组（7.29%vs.17.57%，P＝0.049）；Cox回归分析结果显示，达格列净可减少PCI后MACE的发生（HR＝0.374，95%CI为0.161～0.866，P＝0.022）。结论在水化基础上，使用达格列净并不会增加T2DM合并ACS患者PCI后CIAKI的发生风险。 |
| 英文摘要： | OBJECTIVE To investigate the impact of dapagliflozin on contrast-induced acute kidney injury （CIAKI） and prognosis in patients with diabetes mellitus type 2 （T2DM） and acute coronary syndrome （ACS） who underwent percutaneous coronary intervention （PCI）. METHODS Retrospective selection of data on T2DM patients with ACS who underwent PCI treatment in the Cardiology Department of Tianjin Chest Hospital from January 1st 2021 to December 31st 2022. The patients were divided into dapagliflozin group （96 cases） and control group （148 cases） based on whether they received dapagliflozin or not. Renal function indicators were measured for all enrolled patients before PCI and at 48 h and 1 week after PCI， including blood urea nitrogen （BUN）， serum creatinine （Scr）， estimated glomerular filtration rate （eGFR）， cystatin-C （Cys-C）， kidney injury molecule-1 （KIM-1） and β2-microglobulin （β2-MG）. All patients were followed up for at least 1 year. The incidence of CIAKI and major adverse cardiac event （MACE） during follow-up were recorded for both groups. Logistic regression was used to analyze the impact of dapagliflozin on the occurrence of CIAKI， while the Log-rank test was applied to compare the incidence of MACE between the two groups. Cox regression was employed to analyze the impact of dapagliflozin on prognosis. RESULTS At 48 h and 1 week after PCI， serum levels of Cys-C， KIM-1 and β2-MG were significantly lower in the dapagliflozin group compared to the control group （P＜0.05）. The incidence of CIAKI was lower in the dapagliflozin group compared to the control group （6.25% vs. 14.86%， P＝0.042）. Logistic regression analysis revealed that dapagliflozin was an independent protective factor against CIAKI （OR＝0.280， 95%CI 0.101-0.780，P＝0.015）. During the follow-up period， the incidence of MACE was lower in the dapagliflozin group compared to the control group （7.29% vs. 17.57%， P＝0.049）. Cox regression analysis indicated that dapagliflozin reduced the occurrence of MACE after PCI （HR＝0.374， 95%CI 0.161-0.866， P＝0.022）. CONCLUSIONS With adequate hydration， the use of dapagliflozin does not increase the risk of CIAKI following PCI in T2DM patients with ACS. |
| 期刊： | 2025年第36卷第04期 |
| 作者： | 郝慧芳；窄秀凤；李青；杨世诚；张鹏 |
| 英文作者： | HAO Huifang，ZHAI Xiufeng，LI Qing，YANG Shicheng，ZHANG Peng |
| 关键字： | 达格列净；急性冠脉综合征；2型糖尿病；经皮冠状动脉介入治疗；造影剂；急性肾损伤；预后 |
| KEYWORDS： | dapagliflozin； acute coronary syndrome； diabetes mellitus type 2； percutaneous coronary intervention； contrast； |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！